Inquiry Basket
Loading ......
Filter By Product Search for
GSK3A
GSK3A Full Name
glycogen synthase kinase 3 alpha
GSK3A Introduction
Glycogen synthase kinase 3 alpha (GSK3A) is a constitutively active serine/threonine protein kinase belonging to the GSK3 family, functioning as a central regulator of intracellular signaling networks that many patients and researchers encounter indirectly through complex disease phenotypes rather than a single pathway. Unlike typical kinases that require activation, GSK3A is unusually active under basal conditions and becomes inhibited in response to upstream signals such as insulin, Wnt/β-catenin, and growth factor pathways, making it a key integration node for metabolic control, neuronal signaling, and cellular stress responses. Its activity influences glycogen metabolism, gene transcription, and protein phosphorylation cascades that regulate cell fate decisions. In recent literature, GSK3A has gained increasing attention as a context-dependent regulatory kinase whose dysregulation is associated with multi-system diseases, particularly where signaling imbalance leads to progressive pathology rather than acute dysfunction.
Functionally, GSK3A plays broad roles in cytoskeletal organization, intracellular trafficking, and signal transduction, often acting as a "molecular switch" that fine-tunes structural and functional dynamics inside the cell. It regulates microtubule stability, actin remodeling, and cellular polarity, thereby influencing neuronal development, synaptic plasticity, and cell migration. A comprehensive review highlights that GSK3 (including both GSK3A and GSK3B) is a critical regulator of cytoskeleton architecture, with downstream consequences for neuronal morphology, immune cell movement, and tumor cell invasiveness. Beyond structural regulation, GSK3A is also involved in phosphorylation networks that control mitochondrial transport and stress adaptation, making it essential for maintaining cellular homeostasis under both physiological and pathological conditions where patients often experience irreversible functional decline once dysregulated signaling accumulates.
Clinically, GSK3A is increasingly recognized as a disease-relevant target in neurodegeneration, cancer, immunity, and reproductive biology, reflecting its wide biological footprint and the challenge of achieving therapeutic specificity. In Alzheimer's disease, GSK3 (including GSK3A) contributes to amyloid-β production and tau hyperphosphorylation, positioning it as a long-standing but still unresolved therapeutic target. In oncology, emerging evidence shows that Gsk3a promotes immune evasion in hepatocellular carcinoma by enhancing neutrophil recruitment and suppressing cytotoxic T-cell activity, with genetic or pharmacological inhibition improving anti–PD-1 immunotherapy response. Additional studies further link abnormal GSK3A activation to impaired sperm motility under cryodamage conditions, underscoring its sensitivity to cellular stress environments. Collectively, these findings position GSK3A as a multifaceted therapeutic target whose clinical relevance spans chronic degenerative diseases, tumor immune escape, and stress-induced cellular dysfunction, although translation into safe and selective inhibition strategies remains a major challenge in drug development.
Alternate Names for GSK3A
GSK3A; glycogen synthase kinase 3 alpha; glycogen synthase kinase-3 alpha; GSK-3 alpha; serine/threonine-protein kinase GSK3A; DKFZp686D0638
Loading ......
